Click on a filter below to refine your search. Remove a filter to broaden your search.
A review generally revealed low-certainty evidence, particularly for longer-term effects.
Reductions were seen across ages, continents and health statuses.
A small reduction in mortality was seen with use of hydrocortisone with fludrocortisone.
The findings were for middle- and older-aged men and women.
However, no associations was seen for blood pressure or cholesterol levels.
Greater improvements were seen for blood pressure, blood sugar levels and weight control versus the DASH diet.
Paxlovid has been taken by older adults and others at high risk for severe COVID-19 under an emergency use approval.
Significant improvement also was seen in lung function, quality of life and severity of COPD symptoms.
The enhanced automatic insulin delivery system was cleared for people with type 1 diabetes aged ≥6 years.
Strong recommendations were made for the use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride.